Effect of sacubitril/valsartan combined with dapagliflozin on long-term cardiac mortality in heart failure with reduced ejection fraction

Basit Öğe Kaydı
dc.contributor.authorKarabulut, Umut
dc.contributor.authorKeskin, Kudret
dc.contributor.authorKarabulut, Dilay
dc.contributor.authorYiğit, Ece
dc.contributor.authorYiğit, Zerrin
dc.date.accessioned2022-12-27T12:57:15Z
dc.date.available2022-12-27T12:57:15Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractThe angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan and sodium-glucose cotransporter-2 (SGLT-2) inhibitor dapagliflozin have been shown to reduce rehospitalization and cardiac mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF). We aimed to compare the long-term cardiac and all-cause mortality of ARNI and dapagliflozin combination therapy against ARNI monotherapy in patients with HFrEF. This retrospective study involved 244 patients with HF with New York Heart Association (NYHA) class II-IV symptoms and ejection fraction <= 40%. The patients were divided into 2 groups: ARNI monotherapy and ARNI+dapagliflozin. Median follow-up was 2.5 (.16-3.72) years. One hundred and seventy-five (71.7%) patients were male, and the mean age was 65.9 (SD, 10.2) years. Long-term cardiac mortality rates were significantly lower in the ARNI+dapagliflozin group (7.4%) than in the ARNI monotherapy group (19.5%) (P = .01). Dapagliflozin [Hazard Ratio (HR) [95% Confidence Interval (CI)] = .29 [.10-.77]; P = .014] and left ventricular ejection fraction (LVEF) [HR (95% CI) = .89 (.85-.93); P < .001] were found to be independent predictors of cardiac mortality. Our study showed a significant reduction in cardiac mortality with ARNI and dapagliflozin combination therapy compared with ARNI monotherapy.
dc.identifier.citationKarabulut, U., Keskin, K., Karabulut, D., Yiğit, E. ve Yiğit, Z. (2022). Effect of sacubitril/valsartan combined with dapagliflozin on long-term cardiac mortality in heart failure with reduced ejection fraction. Angiology, 73(4), 350-356. https://doi.org/10.1177/00033197211047329
dc.identifier.doi10.1177/00033197211047329
dc.identifier.endpage356
dc.identifier.issn0003-3197
dc.identifier.issn1940-1574
dc.identifier.issue4
dc.identifier.pmid34560822
dc.identifier.scopus2-s2.0-85115726167
dc.identifier.scopusqualityQ2
dc.identifier.startpage350
dc.identifier.urihttps://doi.org/10.1177/00033197211047329
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10197
dc.identifier.volume73
dc.identifier.wos000703105200001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYiğit, Ece
dc.language.isoen
dc.publisherSAGE Publications Inc
dc.relation.ispartofAngiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCombination Therapy
dc.subjectDapagliflozin
dc.subjectHeart Failure
dc.subjectMortality
dc.subjectSacubitril
dc.subjectValsartan
dc.titleEffect of sacubitril/valsartan combined with dapagliflozin on long-term cardiac mortality in heart failure with reduced ejection fraction
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu